<DOC>
	<DOC>NCT00674947</DOC>
	<brief_summary>Phase 1, open-labeled, safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.</brief_summary>
	<brief_title>A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Age 18 years or older at the time of informed consent. Solid tumors that are relapsed or refractory to at least 1 prior anticancer systemic therapy and for which no standard therapy exists. ECOG Performance Status &lt;/= 2. Exclusion Criteria History of keratoconjunctivitis, open or closed angle glaucoma, or "dry eye" disease. New York Heart Association (NYHA) Grade II or greater congestive heart failure. History of myocardial infarction within 6 months prior to Day 1. Presence of &gt;/= Grade 2 peripheral neuropathy. Known presence of central nervous system or brain metastases. Prior therapy with a conjugated or unconjugated maytansine derivative.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>